SCHEMBL6629758

SCHEMBL6629758

CCC(NC(=O)CCS(=O)(=O)Cc1ccccc1OC(F)F)[C@@H](O)C(=O)NCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 1/20 0.37
KMT2A Q03164 5/20 0.37
MEN1 O00255 2/20 0.36
PSMB1 P20618 1/20 0.35
CTSD P07339 2/20 0.35
BACE1 P56817 1/20 0.35
MAPT P10636 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA3 P07451 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34
CA5A P35218 1/20 0.34
CA7 P43166 1/20 0.34
CACNA1C Q13936 1/20 0.34
SCN9A Q15858 1/20 0.34
CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6630402 1.00 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2POLBKMT2AMEN1
SCHEMBL6062997 0.83 CAPN1 (0.47) ALDH1A1SMN1; SMN2POLBKMT2A
SCHEMBL6062452 0.78 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1
SCHEMBL6062945 0.74 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL6062653 0.73 ALDH1A1 (0.43) ALDH1A1KMT2AMEN1
SCHEMBL6062764 0.73 KMT2A (0.44) ALDH1A1SMN1; SMN2POLBKMT2AMEN1
SCHEMBL6630648 0.73 KMT2A (0.65) ALDH1A1SMN1; SMN2POLBKMT2AMEN1
SCHEMBL6695177 0.71 MAP3K7 (0.41) ALDH1A1KMT2AMEN1
SCHEMBL6062378 0.70 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2POLBKMT2AMEN1
SCHEMBL14426917 0.69 TNF (0.40) ALDH1A1POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2004-07-22 US disclosed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 EP disclosed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142999-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE ALDH1A1 4046/4885SMN1; SMN2 3350/4885POLB 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.